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Abstract 
Immune responses to cancer are dynamic processes which take place through the concerted 
activity of innate and adaptive cell populations. In order to fully understand the efficacy of 
immune therapies for cancer, it is critical to understand how the treatment modulates the 
function of each cell type involved in the anti-tumor immune response. Molecular imaging is a 
versatile method for longitudinal studies of cellular localization and function. The develop-
ment of reporter genes for tracking cell movement and function was a powerful addition to 
the immunologist’s toolbox. This review will highlight the advances and challenges in the use 
of reporter gene imaging to track immune cell localization and function in cancer. 
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Introduction 
The immune system has the capacity to recog-
nize and destroy malignant cells, a process which is 
thought  to  occur  regularly  during  the  mammalian 
lifespan. Immune surveillance of cancer is mediated 
by both innate and adaptive cells [1], whose interac-
tion  determines  whether  the  outcome  will  be  pro-
gressive  tumor  growth  or  tumor  rejection.  Innate 
immune cells comprise myeloid-derived cells such as 
natural killer cells, and phagocytes such as dendritic 
cells,  macrophages,  and  neutrophils,  which  engulf 
and  remove  pathogens  from  tissues  and  peripheral 
blood.  Immune  surveillance  of  nascent  transformed 
cells includes destruction of tumor cells by these pro-
fessional  phagocytes.  In  addition,  these  innate  im-
mune  cells  can  modulate  the  function  of  adaptive 
immune cells throughout tumor progression, by dif-
ferential production of cytokines and chemokines.  
  Mature B and T cells, the broad categories of 
adaptive immune cells, mature in the bone marrow 
and  thymus,  respectively.  Antibodies  are  produced 
by B cells in response to antigens presented by den-
dritic cells and macrophages. Thymus-derived T cells 
include CD8+ cytotoxic T cells with direct lytic capac-
ity, CD4+ helper T cells which shape the immune re-
sponse by production of cytokines, and CD4+FoxP3+ 
regulatory  T  cells  which  modulate  the  function  of 
both CD8+ and CD4+ T cells. Antigens presented by 
innate immune cells can activate all three types of T 
cells,  which  then  either  augment  or  inhibit  tumor 
growth [2].  
 Thus, the interaction between innate and adap-
tive  immune  cells  within  the  tumor  microenviron-
ment  modulates  cancer  development  and  progres-
sion. Currently, this dynamic process is largely eval-
uated with snapshots in time and space. Immune cells 
harvested from tumor biopsies, excised tumor tissue, 
or  peripheral  blood  are  analyzed  by  immunohisto-
chemistry or flow cytometry to determine the number 
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and functional status of cells within the  tumor and 
host.  Although  highly  informative,  these  analyses 
cannot evaluate changes in cell numbers or functional 
status  within  the  same  living  subject.  Functional 
changes  over  time  are,  thus,  evaluated  using  serial 
measurements  of  multiple  experimental  animals  in 
pre-clinical models, and multiple biopsies in patients 
when available.  
 Non-invasive  molecular  imaging  is  uniquely 
poised to provide dynamic spatial and temporal in-
formation on the progress of an immune response in 
living  subjects  [3,  4].  Approaches  to  track  immune 
cells  have  utilized  both  direct  and  indirect  labeling 
methods. Direct labeling approaches for MRI and PET 
have  been  used  to  image  both  adaptive  and  innate 
immune cells, and have been reviewed elsewhere [5, 
6]. However, the label is diluted when the cells divide, 
thus providing only a limited time frame for tracking 
cell movement in vivo. In contrast, indirect labeling via 
genetic  introduction  of  reporter  genes  permanently 
marks cells of interest, permitting long-term tracking 
of immune responses. In addition, false positives are 
avoided,  since  dead  cells  do  not  produce  an  en-
zyme-substrate reaction and, thus, do not emit a sig-
nal. This review will highlight the progress made in 
tracking  immune  cell  localization  and  function  in 
cancer using non-invasive whole-body reporter gene 
imaging,  and  discuss  the  limitations  of  current  ap-
proaches. Cell-cell interactions in the immune system 
have  been  studied  using  fluorescent  reporter  genes 
and intravital microscopy techniques, and have been 
reviewed elsewhere [7, 8].  
 
Figure 1: Introduction of imaging reporter genes into immune cell populations to follow an anti-tumor response. (i) 
Micro-injection of reporter gene DNA into fertilized oocytes to create transgenic mice. Genomic tail DNA is screened for presence of the 
transgene. Expression of the reporter gene is then determined by analysis of bone marrow, spleen or thymus cell populations, generally 
by flow cytometry. If a cell or tissue-restricted promoter is used, specificity is confirmed by analysis of reporter gene expression in 
individual cell types. The transgenic offspring can either be directly challenged with a tumor cell line to follow immune cell localization 
during tumor growth. Alternately, different immune cell subsets expressing the reporter gene can be adoptively transferred into wild-type 
mice which are then challenged with the tumor to follow immune cell localization/function. (ii) HSPCs (hematopoietic stem progenitor 
cells) are isolated from the bone marrow of wild-type mice, and cultured briefly in vitro for infection with a lentivirus or retrovirus 
expressing a reporter gene construct. Recipient animals are lethally irradiated to ablate the endogenous immune system, and then injected 
with the infected bone marrow cells. The immune system is reconstituted within 6 weeks after transfer of marked bone marrow, and the 
reconstitution process can be followed by bioluminescent or radioisotopic imaging. The reconstituted animals are either directly chal-
lenged with a tumor cell line, to follow cell localization and function, or the marked immune cell populations can be serially transferred into 
secondary recipient animals. (iii) Immune cell populations (generally T cells) are isolated from peripheral blood (PBL) or spleen, stimulated 
to proliferate in vitro and infected with a lentivirus or retrovirus expressing the reporter construct, following short term culture. The 
labeled cell population is then injected into immune competent or immune deficient mice to study their localization and function at the site 
of a tumor. Theranostics 2012, 2(4) 
 
http://www.thno.org 
357 
Reporter genes commonly used for imaging 
immune cells 
 Reporter  genes  have  been  developed  for  both 
radioisotopic and optical non-invasive imaging tech-
niques.  For  pre-clinical  imaging,  optical  methods 
provide greater sensitivity of signal, while radioiso-
topic  techniques  are  applicable  for  imaging  in  pa-
tients.  The  strengths  and  limitations  of  these  two 
techniques have been recently reviewed [5, 9, 10] . 
 Several  reporter  genes  for  single-  and  mul-
ti-modality  imaging  have  been  developed  [11].  The 
most  widely  used  bioluminescent  reporter  gene  is 
Firefly luciferase, derived from the firefly  Phontinus 
pyralis  [12].  Its  substrate,  luciferin,  requires  oxygen 
and ATP, and emits a strong signal particularly close 
to the body surface. Codon-optimized versions of this 
enzyme can detect as few as 3 T cells localized sub-
cutaneously in a mouse [13].  
 Renilla  luciferase,  derived  from  the  sea  pansy 
Renilla  reniformis,  uses  the  substrate  coelenterazine 
[13].  Mutated  versions  of  Renilla  luciferase  with 
greater  stability  and  signal  strength  have  also  been 
created [14]. Although the emission spectra of Firefly 
and Renilla luciferase overlap, their kinetics of emis-
sion  are  very  different,  permitting  dual  imaging  of 
two signals in the same animal, nearly simultaneous-
ly. Gaussia luciferase [15] also uses coelenterazine as 
its substrate and can be either secreted, or membrane 
tethered  [16].  Secreted  Gaussia  luciferase  in  the  su-
pernatant can be quantified to determine activity in 
the  cell  population,  while  the  number  of  cells  ex-
pressing the membrane-tethered variant can be ana-
lyzed by flow cytometry. 
 For  radioisotopic  molecular  imaging,  the  viral 
thymidine kinase gene remains the reporter gene of 
choice. The most widely used is Herpes Simplex Virus 
Thymidine Kinase (HSV-TK) [4], and both wild-type 
and mutated versions of this enzyme are used for PET 
imaging. Both  18F-labeled and  124I-labeled substrates 
have  been  developed  which  are  phosphorylated  by 
mutant or wild-type HSV-TK [17]. Recently, a mutant 
human thymidine kinase 2 gene was created which 
phosphorylates a substrate for viral thymidine kinase 
[18, 19]. The human thymidine kinase as a PET re-
porter  gene  is  advantagenous  since  it  is 
non-immunogenic  in  humans,  thus  alleviating  the 
potential problem of rejection of cells transduced with 
the viral thymidine kinase. 
 Fluorescent reporter genes incorporated in im-
aging constructs include GFP or red fluorescent pro-
tein (RFP). Generally, these genes are used for quan-
titation of infected cells, but not non-invasive imaging 
of  immune  cells,  since  sensitivity  and  resolution  of 
these reporters is lower than both bioluminescent and 
radioisotopic imaging reporters.  
 Several  groups  have  developed  multipurpose 
reporters,  which  incorporate  a  fluorescent,  biolumi-
nescent and radioisotopic reporter in the same con-
struct  [20-22].  This  approach  allows  quantitation  of 
the number of reporter gene-expressing cells using the 
fluorescent  reporter,  and  sequential  bioluminescent 
and radioisotopic imaging of the same animal. Con-
sequently, the sensitivity of bioluminescence is com-
bined  with  the  spatial  resolution  of  PET  imaging, 
providing  a  comprehensive  picture  of  the  immune 
response. Multi-modality reporter constructs are cre-
ated by making direct fusions of all three elements 
separated by flexible linkers, or expressing the indi-
vidual  elements  on  the  same  cistron,  separated  by 
internal  ribosomal  entry  site  elements  or  ribosomal 
slippage sites [23]. A possible limitation of these fu-
sion genes may be attenuated signal from one or more 
of the components, compared with expression of each 
reporter  gene  alone.  Thus,  the  advantage  of  multi-
modality imaging should be weighed together with 
the potential loss of signal strength. Both single mo-
dality and multimodality fusion reporters have been 
used to image immune cell subsets.  
Marking immune cell populations with re-
porter genes 
 In order to dissect the interaction of different cell 
types in vivo, expression of a reporter gene must be 
driven  behind  a  cell  type-specific  promoter.  One 
means  of  obtaining  restricted  reporter  gene  expres-
sion is creation of transgenic mice. One of the earliest 
reports which studied T cell localization by reporter 
gene  imaging  used  the  T-cell  specific  human  CD2 
promoter to drive expression of the Firefly luciferase 
reporter  gene  in  all  T  cells.  This  transgenic  mouse 
strain was crossed with CD8+ [24] or CD4+ [25] T cell 
receptor transgenic mice, creating double transgenic 
animals  with  expression  of  luciferase  in  anti-
gen-specific  CD8+  T  cells  or  CD4+  T  cells,  respec-
tively. This powerful approach permits longitudinal 
tracking  of  antigen-specific  T  cells  in vivo,  and  has 
been used to follow responses to model antigens. The 
kinetics of T cell localization to transplantable tumors 
can  be  directly  evaluated  by  challenging  the  trans-
genic mice with transplantable tumors expressing the 
model antigen. The limitation of this approach, how-
ever,  is  the  need  to  create  two  different  transgenic 
strains of mice, which can each track only one model 
antigen.  
 Control of T cell function by Tregs prevents ex-
pansion  and  effector  activity  of  CD8+  and  CD4+  T 
cells which respond to cancers. Modulation of Tregs Theranostics 2012, 2(4) 
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has been widely used as a means of augmenting an-
ti-tumor  immune  responses  in  animal  models,  and 
also in the clinic [26, 27]. The ability to visualize Tregs 
in vivo would provide an important means of tracking 
the effects of Tregs on vaccinations or other therapies 
intended  to  increase  effector  T  cell  numbers  and 
function. Several different strains of mice have been 
created  using  knockin  or  knockout  technology  (re-
viewed in [28]) with fluorescent and/or biolumines-
cent  reporters  expressed  alone  under  the  control  of 
FoxP3 regulatory elements, or driving a fusion or bi-
cistronic protein which includes a reporter gene to-
gether with the FoxP3 coding sequence. These strains 
have been used to study normal Treg function, but so 
far have not been used to study responses to tumors.  
 Dendritic cells, macrophages and neutrophils in 
cancers all have context-dependent functions of T cell 
activation or inhibition, and the interaction of these 
cells with T cell subsets modulates tumor progression 
[2]. A transgenic mouse was created driving expres-
sion of GFP behind the Lysozyme M (LysM) promoter 
[29], and was used to track macrophage localization in 
infection.  Intra-tumoral  macrophages  can  augment 
effector cell function in cancer, depending on the cy-
tokines, chemokines, or activation products produced 
by the tumor or the macrophages themselves. In vivo 
visualization  of  the  waxing  and  waning  of  this  cell 
population  in  tumors  would  dissect  another  im-
portant arm of the antitumor response.  
 Dendritic  cells  (DCs),  the  professional  antigen 
presenting cells of the immune system, are also stud-
ied as a potential cancer therapy. Adoptive transfer of 
this cell population after modification in vitro can ac-
tivate effector immune responses against tumors and 
modulate autoimmune responses. DCs purified from 
a  Firefly  luciferase-expressing  transgenic  mouse 
showed the distribution pattern of these cells in the 
recipient host, an important criterion for determining 
the ability of transferred cells to induce an immune 
response in the target tissue [30]. 
 An  approach  which  bypasses  creation  of  sub-
set-specific  transgenic  reporter  mice  is  adoptive 
transfer of individual cell populations isolated from 
an animal expressing luciferase behind a ubiquitous 
constitutive promoter such as β-actin [31]. The con-
tribution of the labeled cell population to responses in 
an  immune  competent  animal  can  then  be  studied. 
However, the endogenous population is often ablated 
prior  to  adoptive  transfer,  perturbing  the  immune 
system.  
 Adoptive  transfer  of  cell  populations  purified 
from autologous hematopoietic stem cells or periph-
eral blood, are used in the clinical setting as a treat-
ment for cancer [32]. Lentivirus and retroviral vectors 
have been used to transduce stem cells [33] and pri-
mary isolated cell populations [34-36] with imaging 
reporter genes. Constitutive expression in all infected 
cells  results  from  LTR-driven  expression  in  retrovi-
ruses. This approach was used to visualize the locali-
zation of CD8+ T cells to a virally induced tumor [37]. 
Splenocytes of mice which had previously rejected a 
challenge of the Murine Sarcoma Virus/Murine Leu-
kemia Virus were isolated and infected with a retro-
viral construct expressing a HSV-TK-GFP fusion pro-
tein. GFP+CD8+ T cells were isolated and adoptively 
transferred  into  immune  deficient  mice  bearing  the 
virally  induced  tumor.  The  localization  of  these 
memory CD8+ T cells was monitored by PET imaging 
using  18F-FHBG as the substrate. This study demon-
strated  that  serial  PET  imaging  could  be  used  to 
monitor T cell localization to a growing tumor. In a 
conceptually similar study, a human T cell line was 
retrovirally transduced with the HSV-TK PET report-
er  gene  and  localization  to  an  Epstein  Barr  Vi-
rus-expressing  tumor  was  demonstrated  using 
124I-FIAU as the substrate [38]. This approach has also 
been used to demonstrate the homing and survival in 
vivo of bone marrow-derived dendritic cells derived 
and transduced with a GFP and Firefly luciferase fu-
sion protein ex vivo [36].  
 Ubiquitous or cell-type specific expression can 
be achieved in lentiviruses, where reporter gene ex-
pression is driven by internal tissue- or cell-specific 
promoters.  Control  elements  from  the  human  CD4 
promoter  were  used  to  drive  CD4  T  cell-restricted 
expression  of  Green  Fluorescent  Protein  (GFP)  in  a 
lentiviral construct [39]. This reporter construct was 
slightly  leaky,  with  GFP  expression  observed  in  a 
fraction of other T cells and B cells [40]. Nevertheless, 
the  largely  CD4-restricted  expression  allowed  flow 
cytometric monitoring of these cells following adop-
tive transfer of the labeled population, and would be 
useful for tracking the contribution of CD4+ T cells to 
an anti-tumor immune response in vivo. However, this 
strategy may have limited application since genomic 
control regions may be as far as 100 kb removed from 
the  minimal  promoter  [41],  and  placing  regulatory 
elements  outside  their  genomic  context  often  abro-
gates specificity.  
 A potential adverse effect of retroviral or lenti-
viral infection is mutation resulting from the site of 
insertion of the viral genome, which may activate a 
proto-oncogene  or  inactivate  a  tumor  suppressor 
gene, leading to transformation of the transduced cell 
population [42-44]. In addition, immune function of 
the infected cell may be altered by viral infection.  
 Adoptive transfer of reporter gene-labeled cells 
into immune competent mice poses the potential risk Theranostics 2012, 2(4) 
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of immune elimination of the transferred cells which 
recognize the reporter gene as a foreign antigen, and 
has been observed in some instances [45-48]. Mutated 
versions of human thymidine kinase 2 have been re-
ported  which  also  react  with  PET  reporter  probes 
developed for viral thymidine kinase [18, 19]. The use 
of  human  thymidine  kinase  would  prevent  an  im-
mune response against the reporter gene, making this 
type of reporter more useful for clinical imaging.  
 An alternative approach is to introduce the re-
porter gene into hematopoietic stem cells. An intact 
naive immune system with reporter gene labeled cell 
populations  can  be  created  by  infection  of  hemato-
poietic stem/progenitor cells with lentiviral and ret-
roviral  constructs.  Adoptive  transfer  of  the  infected 
progenitor population into lethally irradiated recipi-
ents  creates  an  immune  system  with  bone  mar-
row-derived  myeloid  and  lymphoid  cells  marked 
with  imaging  reporter  genes.  The  reporter  gene  is 
now  a  “self-antigen”,  and  marked  cells  will  not  be 
recognized and eliminated by the host immune sys-
tem.  
 This approach has been used to introduce both 
bioluminescent and radioisotopic reporter genes into 
immune  cell  components  using  ubiquitously  ex-
pressed  promoters  [33],  and  was  used  to  monitor 
primary immune responses to experimental cancers 
[49]. The time course and magnitude of memory re-
sponses to tumor antigens can also be followed with 
this system. This strategy is faster than creation of a 
transgenic  mouse,  and  permits  tracking  of  immune 
responses in any genetic background. The limitations 
for  subset  specificity,  however,  remain  the  same  as 
discussed  above.  Furthermore,  hematopoietic  stem 
cells and primary lymphocytes are relatively resistant 
to infection, and are transduced with low efficiency, 
despite advances in viral gene transfer methodology. 
Thus, only a subset of the responding cell population 
is labeled with the imaging reporter. Nevertheless, the 
extent of labeling is sufficient to monitor cell localiza-
tion to the tumor or site of infection. 
Monitoring immune cell function  
 Activation  of  immune  cells  which  respond  to 
pathogens  or  cancers  is  a  dynamic  process.  For  ex-
ample, T cells require three signals in order to become 
fully functional [50]. Signal 1 is engagement of the T 
cell receptor by interaction with the MHC molecule 
presenting  the  antigen.  Subsequently,  interaction  of 
co-stimulatory receptors on T cells with their ligands 
on antigen-presenting cells delivers Signal 2. Secretion 
of cytokines which serve as growth factors is Signal 3, 
and results in T cell proliferation and effector func-
tion.  The  ability  to  visualize  these  activation  steps 
would  provide  a  more  complete  picture  of  the  an-
ti-tumor  immune  response  and  a  better  gauge  of 
therapeutic efficacy. Translocation of the transcription 
factor NF-AT (Nuclear Factor of Activated T cells) to 
the nucleus rapidly follows ligation of the T cell re-
ceptor, and activates transcription of cytokine genes 
[51]. A lentivirus was created using the NF-AT DNA 
binding  region,  which  controlled  expression  of  the 
HSV-TK PET reporter gene. Infection of a T cell line 
with this lentivirus allowed visualization of Signal 1 
after  TCR  triggering  with  anti-CD3  antibody  [52]. 
Infection  of  murine  splenocytes  with  a  similar  con-
struct  also  allowed  activation-dependent  expression 
of luciferase, and visualization of activated T cells at 
the site of a tumor [5]. Subsequently, a lentivirus con-
struct  was  created  which  permitted  simultaneous 
visualization of T cell localization and NF-AT activa-
tion, using one reporter construct [35]. An insulator 
sequence was used to separate two promoters, which 
drove expression of two different luciferase reporter 
genes,  one  constitutive  and  the  other  activa-
tion-dependent.  These constructs permit imaging of 
Signal 1 in T cell activation.  
 However, T cells which receive Signal 1, but not 
Signals 2 and 3 are anergic (unresponsive) and inca-
pable of mounting effective responses [53]. Imaging 
NF-AT-dependent expression of reporter genes does 
not distinguish between anergic and fully responsive 
cells. CD8+ T cells which are fully functional produce 
cytotoxic products such as perforins and granzymes, 
which make holes in target cells. Recently, a lentivirus 
construct  was  reported  which  drove  expression  of 
Firefly luciferase behind the Granzyme B promoter. A 
transgenic CD8+ T cell line was transduced with this 
construct, which expressed luciferase after interaction 
with its cognate antigen, demonstrating that T cells 
with the capacity to lyse target cells can be detected 
using this reporter construct [54].  
Challenges ahead 
 Studies  to  date  have  followed  the  localization 
and function of one cell type in an immune response. 
Since responses to cancers and pathogens involves the 
activity of several innate and adaptive immune cell 
types,  the  development  of  reporter  gene  constructs 
which allow tracking of multiple cell types simulta-
neously within the same animal will provide a more 
complete picture of therapeutic outcome. This can be 
accomplished  by  the  use  of  two  different  imaging 
modalities sequentially, or by using two different bi-
oluminescent reporters with different emisson kinet-
ics, or two fluorescent reporters with non-overlapping 
emission spectra. The limitation, however, is the lack 
of cell-type specific promoters which can be incorpo-Theranostics 2012, 2(4) 
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rated in a viral vector. In addition, for clinical imag-
ing, the use of reporter gene technology requires the 
development of safe and efficient gene transfer vec-
tors. 
Transduction with viral vectors is the most effi-
cient method for introduction of reporter genes into 
hematopoietic stem/progenitor cells and immune cell 
types. However, the cells may be marked with as few 
as one viral copy per cell. Consequently, the reporter 
gene signal may be low, making it difficult to detect 
small numbers of responding immune cells. In addi-
tion,  transduction  of  immune  cells  requires  in vitro 
culture and stimulation with growth factors. Subse-
quent  adoptive  transfer  into  recipients  requires  de-
pletion  of  at  least  some  endogenous  components, 
which  alters  the  normal  immune  system,  and  is  a 
limitation  in  animal  studies.  In  the  clinical  setting, 
myeloablation  is  used  as  pre-conditioning  prior  to 
adoptive transfer of immune cells expanded in vitro 
[55],  and  transfer  of  reporter  gene-marked  immune 
cells would complement this protocol. This “passive 
immunotherapy” approach has been used to test the 
anti-tumor function of chimeric T cells and T cell re-
ceptor transgenic cells. In several instances the lucif-
erase gene has been incorporated in the construct for 
bioluminescent  imaging  and  the  HSV-TK  gene  has 
been incorporated for PET imaging of the transferred 
T  cells  [56-60].  The  incorporation  of  reporter  con-
structs which are surrogates for T cell function will 
further enhance this technology. 
 Active immunotherapy attempts to generate an 
immune response against the cancer, by either block-
ing inhibitory receptors or cell populations, or gener-
ating T cell responses to antigens through vaccination 
of animals or human patients. In these protocols, re-
porter gene imaging has limited utility, since the goal 
is to observe the effect of immune manipulation on 
endogenous cell populations with the tumor or lym-
phoid organs. The identification of “image-able tar-
gets” within the intact immune system for which op-
tical or radioactive tracers can be developed would 
circumvent  this  limitation.  One  such  PET  probe, 
[(18)F]FAC  (1-[2'-deoxy-2'-[(18)F]fluoroarabinofura-
nosyl] cytosine), was used to visualize lymphoid or-
gans and localized activation of anti-tumor T cell re-
sponses [61]. The development of other probes which 
may  selectively  image  immune  activation  are  cur-
rently underway [62]. 
Conclusion   
 The  development  of  reporter  gene  imaging 
methods  has  provided  tumor  immunologists  with 
powerful tools to study immune cell localization and 
function in vivo.  Non-invasive  longitudinal  imaging 
of innate and adaptive immune subsets will reduce 
the  number  of  experimental  animals  needed  to 
achieve significant results, since the variation inherent 
in the analysis of different animals for several time 
points will be reduced. In preclinical models of ther-
apy,  the  interaction  of  more  than  one  immune  cell 
subset  can  be  studied  nearly  simultaneously. 
Non-invasive whole body imaging allows concurrent 
analysis of different anatomical locations, further ac-
celerating  evaluations  of  therapeutic  efficacy.  Thus, 
with the inclusion of reporter gene imaging in pre-
clinical  studies  and  clinical  trials,  novel  immune 
therapies for cancer may be translated for use in pa-
tients at a more rapid pace.  
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